QIAGEN N.V. introduced a wave of expansion across its QIAcuity digital PCR (dPCR) ecosystem. The updates focus heavily on building out advanced gene expression capabilities, diversifying available assay content, and standardizing end-to-end analytical workflows. This technical expansion arrives as life science researchers and biopharmaceutical developers increasingly transition away from traditional quantitative PCR (qPCR) setups in favor of dPCR’s superior sensitivity, precision, and multiplexing capacity.
By integrating these new gene expression tools, laboratory automation partnerships, and specialized analysis software, QIAGEN aims to accelerate the adoption of digital PCR across large-scale molecular biology research and regulatory compliance environments.
“Gene expression represents one of the largest application areas in molecular biology and a significant opportunity for digital PCR,” said Thierry Bernard, CEO of QIAGEN. “By expanding the QIAcuity ecosystem with new assays, enhanced multiplexing capabilities and workflow solutions, we are helping customers apply digital PCR to a broader range of research and biopharma applications.”
Also Read: Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
Expanding the QIAcuity Digital PCR Framework
The updated QIAcuity portfolio delivers key operational updates across four core segments of the biotechnology and life sciences market:
1. Advanced Gene Expression Solutions for dPCR
QIAGEN intends to expand its testing commercial lines later in 2026 by rolling out new QIAcuity Gene Expression Assays. The upcoming products are optimized to support precise expression profiling across human, mouse, and rat research models. Additionally, the developer plans to launch the QIAcuity OneStep High Multiplex Probe PCR Kit, a solution designed to maximize sample utility by enabling complex, high-order multiplex targets to run simultaneously inside a single nanoplate partition.
2. Enhanced Quality Control for Cell and Gene Therapy (CGT)
To support the stringent manufacturing regulations governing biopharmaceutical production, QIAGEN is building out its residual DNA testing suite. The expansion includes new quantification kits optimized for an array of producer cell systems. These tools enable biopharma operations to achieve reproducible, high-precision analytics during process development, batch release testing, and host-cell impurity monitoring.
3. Standardized Laboratory Automation Integration
Recognizing the throughput demands of industrial and clinical research laboratories, QIAGEN has partnered with Hamilton to automate the initial handling of QIAcuity nanoplate configurations. By transitioning fluid transfer, loading, and setup workflows to automated liquid handling systems, the collaboration significantly increases daily laboratory productivity, optimizes reagent usage, and minimizes the human errors inherent to manual pipetting.
4. Automated Analysis and Compliance Reporting via QIAcuity Software 3.5
Concurrently, the upcoming release of QIAcuity Software 3.5 introduces an updated data analysis layer. The software features pre-configured analysis templates and automated reporting frameworks built to standardize data interpretation across distributed laboratory setups. The platform upgrade streamlines verification speeds, making it easier for biopharma networks to preserve data integrity and maintain strict regulatory compliance across high-volume experimental runs.
Driving Data Efficiency via Nanoplate Partitioning
The QIAcuity platform distinguishes itself from legacy infrastructure by utilizing microfluidic nanoplates to disperse a biological sample into thousands of individual, isolated partitions. The system then executes and reads the target reactions simultaneously, allowing it to quantify even faint, low-abundance genetic signals with absolute accuracy. By combining sample partitioning, thermocycling, and optical imaging into a single unified instrument, the platform condenses traditional digital PCR workflows from six hours down to just two.
The comprehensive portfolio updates and software enhancements are scheduled to roll out across global biopharma and life sciences markets throughout the remainder of 2026. Laboratories can explore platform specifications, review automation integration protocols, and access relevant application notes via the official QIAGEN digital portal.
Source: BusinessWire